Recombinant Mouse Galectin-3 protein (His Tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
His Tag
Activity
not tested
Cat no : Eg1232
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Mouse Galectin-3 protein Met1-Ile264 (Accession# P16110) with a his tag at the N-terminus. |
| GeneID | 16854 |
| Accession | P16110 |
| PredictedSize | 28.6 kDa |
| SDS-PAGE | 33-37 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Galectins are a family of animal lectins defined by shared characteristic amino-acid sequences and affinity for β-galactose-containing oligosac-charides. Galectin-3, a 31-kDa member of the β-galactoside-binding proteins, contains one carbohydrate recognition domain (CRD) and a proline- and glycine-rich N-terminal domain through which is able to form oligomers. Galectin-3 is widely expressed in many normal tissues and a variety of tumors. It is found intracellularly in nucleus and cytoplasm or secreted outside of cell, being present on the cell surface or in the extracellular space. Galectin-3 is involved in various biological processes including cell growth, adhesion, differentiation, apoptosis, angiogenesis, immune response, neoplastic transformation and metastasis. Elevated serum galectin-3 levels have been reported in patients with breast, gastrointestinal, lung, or ovarian cancer, melanoma, and non-Hodgkin's lymphoma.
References:
1. Barondes SH, et al. (1994) J Biol Chem. 269(33):20807-10. 2. Iurisci I, et al. (2000) Clin Cancer Res. 6(4):1389-93. 3. Takenaka Y, et al. (2002) Glycoconj J. 19(7-9):543-9. 4. Dumic J, et al.(2006) Biochim Biophys Acta. 1760(4):616-35.